Table 3.
Adverse event(s) | During metronidazole treatment phase (days 1–60) |
After metronidazole treatment phase (days > 60) |
||||
---|---|---|---|---|---|---|
No. (%) of patients receiving metronidazole (n = 16) | No. (%) of patients receiving placebo (n = 17) | Relative risk (95% CI) | No. (%) of patients receiving metronidazole (n = 16) | No. (%) of patients receiving placebo (n = 17) | Relative risk (95% CI) | |
Aspergilloma | 1 (6.3) | 0 | ||||
Diarrhea | 1 (6.3) | 1 (5.9) | 1.1 (0.1–15.6) | |||
Fracture | 0 | 1 (5.9) | 0 | |||
Gastritis | 1 (6.3) | 0 | ||||
Hemoptysis | 1 (6.3) | 0 | ||||
Hepatitis/elevated transaminases | 1 (6.3) | 0 | 1 (6.3) | 0 | ||
Hypercholesterolemia | 0 | 1 (5.9) | 0 | |||
Hyperglycemia | 0 | 1 (5.9) | 0 | 1 (6.3) | 1 (5.9) | 1.1 (0.1–15.6) |
Hyperuricemia | 3 (18.8) | 3 (17.6) | 1.1 (0.2–4.5) | 3 (18.8) | 2 (11.8) | 1.6 (0.3–8.3) |
Hypokalemia | 1 (6.3) | 0 | ||||
Myalgia(s) | 0 | 1 (5.9) | 0 | |||
Nausea | 1 (6.3) | 0 | ||||
Peripheral neuropathy | 8 (50.0) | 2 (11.8) | 4.3 (1.1–17.1) | |||
Pneumothorax | 0 | 1 (5.9) | 0 | |||
Rash | 0 | 1 (5.9) | 0 | |||
Seizure | 2 (12.5) | 1 (5.9) | 2.1 (0.2–21.2) | 1 (6.3) | 0 |